Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia

Earlier, we reported that CTLA4 expression is inversely correlated with CD38 expression in chronic lymphocytic leukemia (CLL) cells. However, the specific role of CTLA4 in CLL pathogenesis remains unknown. Therefore, to elucidate the possible role of CTLA4 in CLL pathogenesis, CTLA4 was down-regulated in primary CLL cells. We then evaluated proliferation/survival in these cells using MTT, 3H-thymidine uptake and Annexin-V apoptosis assays. We also measured expression levels of downstream molecules involved in B-cell proliferation/survival signaling including STAT1, NFATC2, c-Fos, c-Myc, and Bcl-2 using microarray, PCR, western blotting analyses, and a stromal cell culture system. CLL cells with CTLA4 down-regulation demonstrated a significant increase in proliferation and survival along with an increased expression of STAT1, STAT1 phosphorylation, NFATC2, c-Fos phosphorylation, c-Myc, Ki-67 and Bcl-2 molecules. In addition, compared to controls, the CTLA4-downregulated CLL cells showed a decreased frequency of apoptosis, which also correlated with increased expression of Bcl-2. Interestingly, CLL cells from lymph node and CLL cells co-cultured on stroma expressed lower levels of CTLA4 and higher levels of c-Fos, c-Myc, and Bcl-2 compared to CLL control cells. These results indicate that microenvironment-controlled-CTLA4 expression mediates proliferation/survival of CLL cells by regulating the expression/activation of STAT1, NFATC2, c-Fos, c-Myc, and/or Bcl-2.

[1]  P. Bierman,et al.  Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect. , 2006, International journal of molecular medicine.

[2]  A. Kristof,et al.  Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8. , 2008, Blood.

[3]  C. Quilici,et al.  CTLA4Ig Alters the Course of Autoimmune Disease Development in Lyn−/− Mice , 2009, The Journal of Immunology.

[4]  Andreas Radbruch,et al.  CD152 (CTLA-4) Determines the Unequal Resistance of Th1 and Th2 Cells against Activation-induced Cell Death by a Mechanism Requiring PI3 Kinase Function , 2004, The Journal of experimental medicine.

[5]  J. Leonard,et al.  Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L , 2012, The Journal of Immunology.

[6]  S. Fillatreau,et al.  A New Role of CTLA-4 on B Cells in Thymus-Dependent Immune Responses In Vivo1 , 2007, The Journal of Immunology.

[7]  E. Serfling,et al.  Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. , 1996, Leukemia & lymphoma.

[8]  L. Rassenti,et al.  Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia , 2005, Leukemia.

[9]  P. Linsley,et al.  Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. , 1997, Transplantation.

[10]  G. Freeman,et al.  B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. , 1997, Journal of immunology.

[11]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[12]  S. Malek,et al.  Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.

[13]  Susan O'Brien,et al.  Chronic lymphocytic leukemia , 2011 .

[14]  A. Sharpe,et al.  CTLA‐4 regulates cell cycle progression during a primary immune response , 2002, European journal of immunology.

[15]  L. Staudt,et al.  Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs , 2004, BMC Immunology.

[16]  A. Sheriff,et al.  Lentiviral gene transfer of CTLA4 generates B cells with reduced costimulatory properties , 2009, Autoimmunity.

[17]  I. Frydecka,et al.  CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients , 2005, Leukemia.

[18]  A. Cross,et al.  T cells are the main cell type expressing B7‐1 and B7‐2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis , 1999, European journal of immunology.

[19]  H. Döhner,et al.  Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. , 2006, Blood.

[20]  A. Rosenwald,et al.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies. , 2009, Blood.

[21]  D. Weisenburger,et al.  Fluorescence in situ Hybridization Detection of Cytogenetic Abnormalities in B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , 2004, Leukemia & lymphoma.

[22]  M. Rossi,et al.  Poly(ADP-ribosyl)ation is implicated in the G0–G1 transition of resting cells , 2008, Oncogene.

[23]  D. Weisenburger,et al.  Hedgehog-Induced Survival of B-Cell Chronic Lymphocytic Leukemia Cells in a Stromal Cell Microenvironment: A Potential New Therapeutic Target , 2008, Molecular Cancer Research.

[24]  Andrew W. Greaves,et al.  Cyclic nucleotide phosphodiesterase 7B mRNA: An unfavorable characteristic in chronic lymphocytic leukemia , 2011, International journal of cancer.

[25]  C. Croce,et al.  Surface Expression of Bcl-2 in Chronic Lymphocytic Leukemia and Other B-Cell Leukemias and Lymphomas Without a Breakpoint t(14;18) , 2008, Molecular medicine.

[26]  D. Spaner,et al.  Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity1 , 2006, The Journal of Immunology.

[27]  M. Pistillo,et al.  Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer , 2012, Cancer Immunology, Immunotherapy.

[28]  J. Salisbury,et al.  CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. , 2008, Blood.

[29]  Andrea Iaboni,et al.  The interaction properties of costimulatory molecules revisited. , 2002, Immunity.

[30]  S. Deaglio,et al.  CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. , 2005, Blood.

[31]  T. Shanafelt,et al.  VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance , 2010, Leukemia.

[32]  J. Briones,et al.  Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia , 2005, Leukemia & lymphoma.

[33]  R. Puri,et al.  A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. , 2005, Leukemia research.

[34]  J. Allison,et al.  CTLA-4-Mediated inhibition of early events of T cell proliferation. , 1999, Journal of immunology.

[35]  D. Weisenburger,et al.  Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. , 2007, International journal of molecular medicine.

[36]  M. Mattei,et al.  CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. , 1991, Journal of immunology.

[37]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[38]  A. García-Pardo,et al.  Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. , 2008, Blood.

[39]  A. J. Wilson,et al.  Induction of the CTLA-4 Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter1 , 2007, The Journal of Immunology.

[40]  H. Wodrich,et al.  Heterodimerization with Jun Family Members Regulates c-Fos Nucleocytoplasmic Traffic* , 2007, Journal of Biological Chemistry.

[41]  J. Armitage,et al.  ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38–Expressing B-Cell Chronic Lymphocytic Leukemia , 2007, Clinical Cancer Research.

[42]  T. Dobosz,et al.  Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population. , 2008, Human immunology.

[43]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[44]  C. Thompson,et al.  Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells , 2001, The Journal of experimental medicine.

[45]  H. Reiser,et al.  Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  V. Boussiotis,et al.  Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. , 2008, Blood.

[47]  Agustín Correa,et al.  High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. , 2010, Blood.

[48]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[49]  N. Chiorazzi,et al.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. , 2007, Blood.

[50]  Caleb B. McDonald,et al.  Coupling of folding and DNA-binding in the bZIP domains of Jun-Fos heterodimeric transcription factor. , 2008, Archives of biochemistry and biophysics.

[51]  J. Allison,et al.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. C. Ferrasi,et al.  Relationship Between EBV Infection and Expression of Cellular Proteins c-Myc, Bcl-2, and Bax in Gastric Carcinomas , 2008, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[53]  J. Dürig,et al.  CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia , 2002, Leukemia.

[54]  D. Weisenburger,et al.  Lymph node‐induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin‐1 , 2012, British journal of haematology.